# Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.

> **NCT05142553** · PHASE2 · COMPLETED · sponsor: **Hipra Scientific, S.L.U** · enrollment: 887 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2 Acute Respiratory Disease

## Interventions

- **BIOLOGICAL:** COVID-19 Vaccine HIPRA
- **BIOLOGICAL:** Cominarty (Pfizer-BioNtech)

## Key facts

- **NCT ID:** NCT05142553
- **Lead sponsor:** Hipra Scientific, S.L.U
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-16
- **Primary completion:** 2023-05-29
- **Final completion:** 2023-05-29
- **Target enrollment:** 887 (ACTUAL)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05142553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05142553, "Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05142553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*